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Abstract
Background: Venous thromboembolism (VTE) could be manifested as deep venous thrombosis (DVT) or
pulmonary embolism (PE). DVT is usually the more common manifestation and is usually formation of a thrombus
in the deep veins of lower extremities. DVT could occur without known underlying cause (idiopathic thrombosis)
which could be a consequence of an inherited underlying risk factor or could be a consequence of provoking
events, such as trauma, surgery or acute illness (provoked thrombosis). Our aim in this study was to assess the
impact of some previously reported genetic risk factors including, methylenetetrahydrofolate reductase (MTHFR)
C677T and A1298C, plasminogen activator inhibitor-1(PAI-1) 4G/5G, prothrombin 20210 and FV Leiden on
occurrence of DVT in a population of Iranian patients.
Methods: This long-term study was conducted on 182 patients with DVT and also 250 age and sex matched
healthy subjects as control group. The diagnosis of DVT was based on patient’s history, clinical findings, D-dimer
test, and confirmed by Doppler ultrasonography. After confirmation of DVT, both groups were assessed for the five
mentioned mutations. The relationship between mutations and predisposition to DVT was calculated by using
logistic regression and expressed as an OR with a 95 % confidence interval (CI).
Results: Our results revealed that FV Leiden (OR 6.7; 95 % CI = 2.2 to 20.3; P = 0.001), MTHFR C677T (OR 6.0; 95 % CI = 2.2
to 16.4; P < 0.001), MTHFR A1298C (OR 8.3; 95 % CI = 4.4 to 15.8; P < 0.001), and PAI-1 4G/5G (OR 3.8; 95 % CI = 2.1 to 7.2;
P < 0.001) mutations were all significantly associated with an increased risk of DVT. Prothrombin 20210 was found in none
of the patients and controls.
Conclusion: Our findings suggest that genetic risk factors have a contributory role on occurrence of DVT.
Keywords: Deep venous thrombosis, Plasminogen activator inhibitor-1, FV Leiden, Prothrombin20210,
Methylenetetrahydrofolate reductase
Background
Venous thromboembolism (VTE) which is manifested
either as deep venous thrombosis (DVT) or pulmonary
embolism (PE) is the third most frequent cardiovascular
disorder after myocardial infarction and stroke. DVT is
the thrombotic obstruction of deep veins in the lower
extremities, and is a significant cause of mortality and
morbidity. According to the studies, 1 in 1000 individ-
uals in old age population is complicated by DVT,
annually [1–3].
DVT is a multi-factorial disorder which may occur fol-
lowing a combination of some acquired conditions includ-
ing surgical procedures, hormonal therapy, trauma, cancer,
or immobilization condition (hospitalization), and inherited
risk factors [1]. Based on the studies, genetic factors are
responsible for approximately 60 % DVTcases [4]. Factor V
(FV) Leiden which is the most common cause of inherited
thrombophilia, predisposes patients to DVT because of
resistance to protein C. Prothrombin 20210, another
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common cause of hereditary thrombophilia, is also a risk
factor for DVT [5]. Two common polymorphisms in
methylene tetrahydrofolate reductase (MTHFR) gene in-
cluding C677T and A1298C, lead to decreased enzyme
activity and therefore elevation of homocysteine level.
Several studies have shown that these two polymor-
phisms might be associated with DVT due to hyper-
homocysteinemia [6–9]. Another polymorphism which
is known as a risk factor for DVT is Plasminogen activator
inhibitor-1 (PAI-1) 4G/5G. The 4G allele is associated with
a higher level of PAI-1 in plasma which in turn results in
a decreased fibrinolysis activity and therefore a higher
tendency to thrombus formation [8–10].
There are several studies in the literature which
assessed the genetic risk factors of DVT in different
ethnical populations [11–15]. In this regard the aim
of the current study was to analyze some previously
reported genetic risk factors including, MTHFR
C677T and A1298C, PAI-1 4G/5G, Prothrombin
20210 and FV Leiden on occurrence of DVT in Iranian
population.
Patients and methods
Study population, and data collection
This long-term retrospective study was conducted
from June 2009 to July 2013 on 182 patients with
DVT and also 250 age and sex matched healthy
individuals as control group who referred to Clinical
laboratory. The mean age of patients was 38.3 ±
15.4 years (median = 34, range = 81), 67.6 % of pa-
tients were female and 32.4 % were male. We in-
cluded patients with confirmed DVT who experienced
thrombosis more than once with no specific reason.
The exclusion criteria were defined as incomplete med-
ical history. For control group we randomly selected
250 healthy individuals with no history of thrombosis
who were as similar as possible to the patients group
regarding age and sex (using independent t-test, P =
0.4). The mean age of controls was 39.7 ± 16.4 years
(median = 36, range = 87), 65.5 % of patients were
female and 34.5 % were male. A written consent was
obtained from all the participants and the study was
approved by the medical ethics committee of local
ethical commitee.
Initially each suspected patient was physically exam-
ined by physician and also was interviewed by a trained
staff about their medical history. The diagnosis of
venous thromboembolic disease was based on patient’s
history, clinical findings and D-dimer test. Finally DVT
was confirmed by Doppler ultrasonography. In addition,
all participants were asked to complete a standard-
ized questionnaire on acquired risk factors of venous
thrombosis.
DNA analysis
Blood samples were collected early in the morning in
EDTA anticoagulant. Collected whole blood samples
were stored at −20 °C for DNA extraction in an appro-
priate time. In the next step DNA was extracted from
thawed whole bloods using QIAAMP DNA blood kit
(Qiagen, Germany). The quality and quantity of the
extracted DNA was determined by spectrophotometer
and also by means of agarose gel electrophoresis.
Isolated DNA samples were then stored at −70 °C for
long-time usage.
Analysis of PAI-1 polymorphism was performed by
amplifying the promoter gene flanking region for 4G/5G
polymorphism. The PCR products of 148-bp DNA
fragments were digested with Bse RI (MBI Fermentas)
according to the protocol provided by the manufacturer.
Digestion products were subjected to electrophoresis on
2 % agarose gel. The presence of 110- and 38-bp DNA
fragments indicated the 4G allele, while the 148-bp frag-
ment indicated the 5G allele. Patients were also screened
for Factor V Leiden, prothrombin 20210, MTHFRA1298C
and MTHFR C677T gene mutations by procedures which
described elsewhere [16–19].
Statistical methods
Results were reported as mean ± standard deviation (SD)
for quantitative variables and percentages for categorical
variables. All the statistical analyses were performed by
SPSS software. The relationship between the PAI-1,
MTHFR and FV Leiden gene polymorphisms and DVT
was calculated using logistic regression and expressed as
an odd ratio (OR) with a 95 % confidence interval (CI).
The combined effect of these polymorphisms on the risk
of DVT was also assessed by logistic regression. For this
purpose we analyzed the risk of DVT in combined inherit-
ance of each two polymorphisms, either in heterozygous or
homozygous manner, in comparison with the single inherit-
ance of the related mutations (as a reference). The P values
less than 0.05 were considered as statistically significant.
Results
Characteristics of the study population
The youngest patient was a 1 year’s female and the
oldest one was also an 82 year-old female. Demographic
data of patients with DVT is shown in Table 1.
Prothrombin 20210, Factor V Leiden, MTHFR and PAI-1
mutations analysis
Distribution of FV Leiden, MTHFRC677T, MTHFRA1298C,
and PAI-1 4G/5G among DVT patients and controls are
indicated in Table 2. Molecular analysis of study population
revealed that in the patients group, 8 (4.4 %) patients
(1 male and 7 female) were homozygous for FV Leiden and
10 (5.5 %) (5 males and 5 females) were carriers for this
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mutation. Prevalence of FV Leiden was 9.9 % in patients
and 1.6 % in controls. Although none of the controls was
homozygous for FV Leiden. Statistical analysis revealed a
significant association between FV Leiden mutation and
DVT (OR 6.7; 95 % CI = 2.2 to 20.3; P = 0.001). Out of 182
patients 17 (9.3 %) (2 males and 15 females) were homozy-
gous for MTHFRC677T and 3 (1.6 %) were carriers.
Among controls 5 were detected with MTHFRC677T mu-
tation, 3 in heterozygous and 2 in homozygous state. The
prevalence of this mutation was 10.9 % in patients and 2 %
in healthy controls, and therefore the association between
MTHFRC677T and DVT were statistically significant (OR
6.0; 95 % CI = 2.2 to 16.4; P < 0.001). Among the studied
mutations it seems that MTHFRA1298C has the highest
prevalence in patients with DVT (31.3 %) and the majority
of patients with this mutation were heterozygote (30.2 %).
The association between MTHFRA1298C and DVT were
also significant (OR 8.3; 95 % CI = 4.4 to 15.8; P < 0.001).
PAI-1 mutation was found in 38 patients with a prevalence
of 20.9 %. Thirty four (18.7 %) out of 38 patients were car-
riers and only 4 (2.2 %) were homozygous. This mutation
was also found in 16 (6.4 %) healthy individuals in heterozy-
gous pattern. A significant association was also found be-
tween PAI-1 4G/5G and the occurrence of DVT (OR 3.8;
95 % CI = 2.1 to 7.2; P < 0.001). However prothrombin
20210 was found in none of the patients and healthy
individuals.
We also assessed the combined effect of the four poly-
morphisms on the risk of DVT; But we found no statisti-
cally significant difference (P > 0.05 for all the 6 possible
combination, including FV Leiden/ PAI-1, FV Leiden/
MTHFR C677T, FV Leiden/ MTHFR A1298C, PAI-1/
MTHFR C677T, PAI-1/ MTHFR A1298C, and MTHFR
C677T/ MTHFR A1298C).
Discussion
Inherited thrombophilia gene mutations are known to
have a contributory role in the occurrence of VTE which
is clinically manifested by DVT and/or PE [1]. According
to the literature the incidence of VTE varies in different
races. There have been several studies with the intention
of investigating genetic risk factors contributing to DVT
in different populations. Akhter et al. indicated a higher
prevalence of 4G allele in patients experiencing DVT in
Indian Asian population [10]. A similar result was also
reported by Shammaa et al. in Lebanese population [20].
In a study on Croatian population by Alfirevic et.al FV
Leiden was reported as the highest and prothrombin
20210 as the second most frequent thrombophilia gene
mutations [11]. In this regard, we designed this study to
investigate the association of five important polymor-
phisms with the occurrence of DVT in Iranian patients.
The incidence of DVT in our studied population was ap-
proximately 2 fold higher in females than in males, a
finding consistent with the study of Janbabai et al. on
northern Iran which noted that DVT is more prevalent
in females [21]. According to our results FV Leiden,
MTHFR C677T, MTHFR A1298C, and PAI-1 4G/5G
mutations were all significantly associated with an in-
creased risk of DVT; but prothrombin 20210 was found
in none of the patients and controls. These findings are
in agreement with the study of Rahimi et al. who showed
that FV Leiden but not Prothrombin 20210 is a risk fac-
tor for DVT in western Iran [22]. In contrast, there are
some reports which failed to find the contributory role
of FV Leiden on occurrence of DVT in Iranian patients
[23, 24]. In the study conducted by Hajsadeghi et al. FV
Leiden and Prothrombin 20210 were introduced as un-
common genetic causes of DVT in Iranian population
from Esfahan city. They found no significant association
between these two polymorphisms and DVT [23]. These
results were supported by the study of Pourgheysari et
al. on VTE in central Iran [24]. In a Meta analysis study
by Simone et al. involving 11,000 cases and 21,000 con-
trols FV Leiden and Prothrombin 20210 were indicated
as moderate risk factors of VTE and the risk was in-
creased in heterozygote carriers of FV Leiden or Pro-
thrombin 20210, however they found no significant
association with DVT and homozygous pattern of
MTHFR C677T [25]. These contradicting data may reflect
the different incidence of various thrombophilia polymor-
phisms in different populations. Based on studies in
Table 1 Demographic data of patients with DVT
FVLeiden MTHFR C677T MTHFR 1298 PAI-1
Homo (AA) Hetero (GA) Homo (TT) Hetero (CT) Homo (CC) Hetero (AC) Homo (4G/4G) Hetero (4G/5G)
Sex
Male 1 (12.5 %) 5 (50 %) 2 (11.8 %) 3 (100 %) 0 (0) 16 (29 %) 1 (25 %) 5 (14.7 %)
Female 7 (87.5 %) 5 (50 %) 15 (88.2 %) 0 (0) 2 (100 %) 39 (71 %) 3 (75 %) 29 (85.3 %)
Age (year)
(mean ± SD) 40.3 ± 12.9 42.1 ± 11.2 36.3 ± 13.4 53.3 ± 9.7 25 ± 2.8 31.3 ± 13.1 34.5 ± 16 34.5 ± 11.6
Median 36 44.5 33 51 25 32 28.5 32
Range 35 31 52 19 4 69 35 55
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Table 2 Distribution of assessed polymorphisms among DVT patients and controls
FV leiden MTHFRC677T MTHFR A1298C PAI-1
Non mutant Hetero Homo Non mutant Hetero Homo Non mutant Hetero Homo Non mutant Hetero Homo
Patients with
DVT (n = 182)
164 (90.1 %) 10 (5.5 %) 8 (4.4 %) 162 (89.0 %) 3 (1.6) 17 (9.3) 125 (68.7 %) 55 (30.2 %) 2 (1.1 %) 144 (79.1 %) 34 (18.7 %) 4 (2.2 %)
Control group
(n = 250)
246 (98.4 %) 4 (1.6 %) 0 (0) 245 (98 %) 3 (1.2 %) 2 (0.8 %) 237 (94.8 %) 9 (3.6 %) 4 (1.6 %) 234 (93.6 %) 16 (6.4 %) 0 (0 %)
OR 6.7 6.0 8.3 3.8
95 % CI 2.2 to 20.3 2.2 to 16.4 4.4 to 15.8 2.1 to 7.2
P. value 0.001 <0.001 <0.001 <0.001
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different parts of Iran it seems that Prothrombin 20210 is
not a significant genetic factor for DVT in Iranian popula-
tion and there seems to be no consistent findings on FV
Leiden.
There are also studies suggesting that combined inher-
itance of different thrombophilia mutations has a signifi-
cant effect on the occurrence of DVT [26, 27], while we
did not find statistically significant difference between co
inheritance of each two polymorphisms and the single
inheritance of the related mutations.
A significant limitation of our study was the lack of
data regarding clinical characteristics of the studied
population such as localization of DVT and acquired
risk factors. Considering that DVT is a multi-factorial
disorder arising from acquired and genetic risk factors,
it is better to assess both clinical and genetic conditions
in DVT patients which lead to a more comprehensive
and reliable conception of its etiology.
Conclusion
Our findings suggest that genetic risk factors have a
contributory role on occurrence of DVT. But still large
studies are required to determine the most important
underlying prothrombophilic gene mutations which lead
to DVT in Iranian population.
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